Stay updated on Alvocidib Biomarker AML Phase 2 Clinical Trial
Sign up to get notified when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.

Latest updates to the Alvocidib Biomarker AML Phase 2 Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4 to indicate the latest page version.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now shows Revision: v3.6.3, updating the site’s revision label from v3.6.2 to reflect a newer version.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page shows a new revision tag (v3.6.2) replacing the previous v3.6.0, signaling an underlying software update behind the page; no study details or displayed content appear to be affected.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page now shows that the study is no longer looking for participants, signaling that enrollment has ceased. It also includes new help/navigation items and a formatting change to the Intervention/Treatment header as part of a UI/text refresh.SummaryDifference0.4%

- Check60 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous Revision: v3.5.4. This represents a version update with no changes to the study content.SummaryDifference0.0%

- Check81 days agoChange DetectedThe page now displays Revision: v3.5.4, updating the site revision from the previous v3.5.3. This indicates a software/version update rather than a change to the study data or layout.SummaryDifference0.0%

Stay in the know with updates to Alvocidib Biomarker AML Phase 2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.